Integrating multiple lines of evidence to assess the effects of maternal BMI on pregnancy and perinatal outcomes in up to 497,932 women

Competing Interest Statement

DAL receives support from several national and international government and charitable research funders, as well as from Medtronic Ltd and Roche Diagnostics for research unrelated to that presented here. All other authors declare no competing interests.

Funding Statement

The views expressed in this paper are those of the authors and do not necessarily reflect views of any funders, person or group listed in funding or acknowledgement statements. This study was supported by the MRC Integrative Epidemiology Unit at the University of Bristol (MC_UU_00011/6), British Heart Foundation (AA/18/7/34219), the European Research Council under the European Union s Seventh Framework Programme (FP/2007-2013) / ERC Grant Agreement (Grant number 669545), the European Union s Horizon 2020 research and innovation programme under grant agreement No 733206 (LifeCycle), the US National Institutes of Health (R01 DK10324, U01 HG004415), the Bristol NIHR Biomedical Research Centre, and the Research Council of Norway through its Centres of Excellence funding scheme (project number 262700), and the Wellcome Trust [Grant number WT220390]. For the purpose of open access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. MCB has received supported from MRC Skills Development Fellowship (MR/P014054/1) and University of Bristol Vice-Chancellor s Fellowship. DAL is a British Heart Foundation Chair (CH/F/20/90003) and NIHR Senior Investigator (NF-0616-10102). JT is supported by an Academy of Medical Sciences (AMS) Springboard Award, which is supported by the AMS, the Wellcome Trust, GCRF, the Government Department of Business, Energy and Industrial Strategy, the British Heart Foundation and Diabetes UK [SBF004\1079]. RMF was funded by a Wellcome Trust and Royal Society Sir Henry Dale Fellowship (WT104150), and is now funded by a Wellcome Trust Senior Research Fellowship (WT220390). RG received funding from the Dutch Heart Foundation (grant number 2017T013), the Dutch Diabetes Foundation (grant number 2017.81.002), and the Netherlands Organization for Health Research and Development (NWO, ZonMW, grant number 543003109). VWVJ received a Consolidator Grant from the European Research Council (ERC-2014-CoG-648916). XL received support from the Nordic Center of Excellence in Health-Related e-Sciences. LS reports funding from a Carlsberg Foundation postdoctoral fellowship (CF15-0899). BF was supported by an Oak Foundation Fellowship and by a grant from the Novo Nordisk Foundation (12955). MCM has received funding from the European Research Council (ERC) under the European Union s Horizon 2020 research and innovation programme (grant agreement number 947684). TAB is supported by the Medical Research Council (MRC) (UK) (MR/K501281/1), the NHMRC (Australia) (GNT1183074 and GNT1157714) and the British Heart Foundation Accelerator Award at the University of Bristol (AA/18/7/34219) and works in/is affiliated with a unit that is supported by the UK Medical Research Council (MC_UU_00011/6). LB is a senior research scholar from the Fonds de la recherche du Quebec-Sante (FRQ-S) and a member of the FRQ-S-funded Centre de recherche du CHUS. MFH was supported by an American Diabetes Association (ADA) Pathways Accelerator Award (1-15-ACE-26). SEH and MCM are partly funded by the Research Council of Norway (project no. 320656, and through its Centres of Excellence funding scheme (project No 262700). JW and RMc are supported by the National Institute for Health and Care Research under its Applied Research Collaboration, Yorkshire and Humber (NIHR200166). Study-specific funding: ALSPAC study funding: The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and MCB, GC and DAL will serve as guarantors for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf); GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. BiB study funding: Born in Bradford is supported by a Wellcome programme grant (WT223601/Z/21/Z: Age of Wonder), a Wellcome infrastructure grant (WT101597MA), a joint Medical Research Council (MRC) and UK Economic and Social Science Research Council (ESRC) programme grant (MR/N024391/1) and a British Heart Foundation Clinical Study Grant (CS/16/4/32482). Funding for DNA extraction and genotyping was from two MRC programme grants (MC_UU_00011/6 and MC_UU_12013/5). DNBC-GOYA study funding: GOYA is nested within the Danish National Birth Cohort which was established with a significant grant from the Danish National Research Foundation. Additional support was obtained from the Danish Regional Committees, the Pharmacy Foundation, the Egmont Foundation, the March of Dimes Birth Defects Foundation, the Health Foundation and other minor grants. The DNBC Biobank has been supported by the Novo Nordisk Foundation and the Lundbeck Foundation. The genotyping for GOYA was funded by the Wellcome Trust (WT 084762). DNBC-PTB (controls) study funding: The Danish National Birth Cohort (DNBC) is a result of major grants from the Danish National Research Foundation, the Danish Pharmacists Fund, the Egmont Foundation, the March of Dimes Birth Defects Foundation, the Augustinus Foundation, and the Health Fund of the Danish Health Insurance Societies. The DNBC biobank is a part of the Danish National Biobank resource, which is supported by the Novo Nordisk Foundation. The generation of GWAS genotype data for the DNBC samples was carried out within the Gene Environment Association Studies (GENEVA) consortium with funding provided through the National Institutes of Health s Genes, Environment, and Health Initiative (U01HG004423; U01HG004446; U01HG004438). EFSOCH study funding: The Exeter Family Study of Childhood Health (EFSOCH) was supported by South West NHS Research and Development, Exeter NHS Research and Development, the Darlington Trust and the Peninsula National Institute of Health Research (NIHR) Clinical Research Facility at the University of Exeter. The opinions given in this paper do not necessarily represent those of NIHR, the NHS or the Department of Health. Genotyping of the EFSOCH study samples was funded by the Wellcome Trust and Royal Society Grant 104150/Z/14/Z. Gen3G study funding: Gen3G was supported by a Fonds de recherche du Quebec en sante (FRQ-S) operating grant (to MFH, grant #20697); a Canadian Institute of Health Reseach (CIHR) Operating grant (to MFH grant #MOP 115071); a Diabete Quebec grant (to PP) and is currently support by CIHR PJT-152989 (LB). Generation R study funding: The general design of the Generation R Study is made possible by financial support from Erasmus MC, University Medical Center Rotterdam, Erasmus University Rotterdam, the Netherlands Organization for Health Research and Development and the Ministry of Health, Welfare and Sport. This project received funding from the European Union s Horizon 2020 research and innovation programme (733206, LifeCycle, 874739, LongITools, 824989 EUCAN-Connect). HAPO study funding: This study was supported by National Institutes of Health (NIH) grants HD-34242, HD-34243, HG-004415, and CA-141688, and by the American Diabetes Association. INMA study funding: This study was funded by grants from Instituto de Salud Carlos III (CB06/02/0041, G03/176, FIS PS09/00432, FIS-FEDER 03/1615, 04/1509, 04/1112, 04/1931, 05/1079, 05/1052, 06/1213, 06/0867, 07/0314, and 09/02647), Fundacio La Marato de TV3 (090430), Generalitat de Catalunya-CIRIT (1999SGR 00241), Conselleria de Sanitat Generalitat Valenciana, and Fundacion Roger Torne, Department of Health of the Basque Government (2005111093), Provincial Government of Gipuzkoa (DFG06/002), and annual agreements with the municipalities of the study area (Zumarraga, Urretxu, Legazpi, Azkoitia y Azpeitia y Beasain). ISGlobal We acknowledge support from the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa 2019-2023 Program (CEX2018-000806-S), and from the Generalitat de Catalunya through the CERCA Program. MoBa study funding: MoBa is supported by the Norwegian Ministry of Health and Care services and the Ministry of Education and Research. NFBC1966 study funding: NFBC1966 received financial support from University of Oulu Grant no. 65354, Oulu University Hospital Grant no. 2/97, 8/97, Ministry of Health and Social Affairs Grant no. 23/251/97, 160/97, 190/97, National Institute for Health and Welfare, Helsinki Grant no. 54121, Regional Institute of Occupational Health, Oulu, Finland Grant no. 50621, 54231 NFBC1966 received financial support from University of Oulu Grant no. 24000692, Oulu University Hospital Grant no. 24301140, ERDF European Regional Development Fund Grant no. 539/2010 A31592. NFBC1986 study funding: NFBC1986 received financial support from EU QLG1-CT-2000-01643 (EUROBLCS) Grant no. E51560, NorFA Grant no. 731, 20056, 30167, USA / NIH 2000 G DF682 Grant no. 50945. This work was supported by the European Union s Horizon 2020 research and innovation program under grant agreement No. 633595 (DynaHEALTH), grant agreement no. 733206 (LifeCycle), grant agreement no. 873749 (LongITools), grant agreement no. 848158 (EarlyCause).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval was obtained for each participating study as detailed below and in supplementary methods. ALSPAC: Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees (NHS Haydock REC: 10/H1010/70). BiB: Ethical approval for the study was granted by the Bradford National Health Service Research Ethics Committee (ref 06/Q1202/48). DNBC-GOYA: The study was approved by the regional scientific ethics committee and by the Danish Data Protection Board. DNBC-PTB: Ethical approval was obtained from the Regional Scientific Ethical Committee of Copenhagen and the study was also approved by the Danish Data Protection Agency. EFSOCH: All women gave informed consent and ethical approval was obtained from the local review committee. FinnGen: The Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District has approved the FinnGen consortium (Nr HUS/990/2017), and the ethical approval of each individual study has been described in detail elsewhere. Gen3G: Ethics approval from the Centre Hospitalier Universitaire de Sherbrooke (CHUS) Ethics Review Board for Studies with Humans. Generation R: The study protocol was approved by the Medical Ethical Committee of the Erasmus MC, University Medical Center Rotterdam and informed consent was obtained for all participants. HAPO: The protocol was approved by the institutional review board at each field center. All participants gave written informed consent. An external data and safety monitoring committee provided oversight. INMA: Informed consent was obtained from all participants and the study was approved by the Hospital Ethics Committees in each participating region. MoBa: The establishment of MoBa and initial data collection was based on a license from the Norwegian Data Protection Agency and approval from The Regional Committees for Medical and Health Research Ethics. The MoBa cohort is currently regulated by the Norwegian Health Registry Act. The current study was approved by The Regional Committees for Medical and Health Research Ethics of South/East Norway (ref 2018/1256). NFBC1966: the study received ethical approval from Ethics Committee of Northern Ostrobothnia Hospital District (EETTMK: 94/2011) and Oulu University, Faculty of Medicine, Oulu, Finland. NFBC 1986: the study received ethical approval from Ethics Committee of Northern Ostrobothnia Hospital District (EETTMK: 108/ 2017) and Oulu University, Faculty of Medicine, Oulu, Finland. UK Biobank: Ethical approval for UKB was obtained from the North West Multi-centre Research Ethics Committee (MREC), and our study was performed under UKB application number 23938.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes